Show simple item record

dc.contributor.authorAbbott, Michael
dc.contributor.authorMcKenzie, Lynda
dc.contributor.authorMoran, Blanca
dc.contributor.authorHeidenreich, Sebastian
dc.contributor.authorHernández, Rodolfo
dc.contributor.authorHocking- Mennie, Lynne
dc.contributor.authorClark, Caroline
dc.contributor.authorClark, Caroline
dc.contributor.authorGomes, Joana
dc.contributor.authorLampe, Anne
dc.contributor.authorBaty, David
dc.contributor.authorMcGowan, Ruth
dc.contributor.authorMiedzybrodzka, Zosia
dc.contributor.authorRyan, Mandy
dc.date.accessioned2022-02-03T11:24:01Z
dc.date.available2022-02-03T11:24:01Z
dc.date.issued2021-08-20
dc.identifier.citationAbbott , M , McKenzie , L , Moran , B , Heidenreich , S , Hernández , R , Hocking- Mennie , L , Clark , C , Clark , C , Gomes , J , Lampe , A , Baty , D , McGowan , R , Miedzybrodzka , Z & Ryan , M 2021 , ' Continuing the sequence? Towards an Economic Evaluation of Whole Genome Sequencing for the Diagnosis of Rare Diseases in Scotland ' , Journal of Community Genetics . https://doi.org/10.1007/s12687-021-00541-4en
dc.identifier.issn1868-6001
dc.identifier.otherPURE: 197311517
dc.identifier.otherPURE UUID: 56e2a6bf-6729-4e4e-8807-dd56f7cfe3ba
dc.identifier.otherScopus: 85113145375
dc.identifier.urihttps://hdl.handle.net/2164/18026
dc.descriptionFunding This research was made possible through access to the data and findings generated by Scotland’s four regional genetics centres at NHS Grampian, Lothian, Tayside and Greater Glasgow and Clyde. These four centres participated in Scotland’s involvement in the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health) and funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. Acknowledgements The authors would like to thank the Scottish Genomes Partnership for their support with this work. The Scottish Genomes Partnership is funded by the Chief Scientist Office of the Scottish Government Health Directorates [SGP/1] and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative (MC/PC/15080). We are grateful for the contributions of the funding bodies; Scottish Regional Genetics centres at NHS Lothian, Tayside, Grampian and Greater Glasgow and Clyde, clinicians and healthcare teams who contributed to the provision of data as well as the analyses and interpretation of results. We also thank Morad Ansari, Christine Bell, Martin McClatchey, Nicola Williams, Austin Diamond, Jonathan Berg, Jon Warner, Alexis Duncan, Amy Rowlatt, and Tessa Coupar for their help and advice during the SGP Project, and Michael Doherty, Florence Richards and Quinn Heppe for help with costing the standard testing pathway. We thank Professor Tim Aitman for commenting on earlier drafts of the paper. We thank all participants who took part in the valuation study. The University of Aberdeen and the Chief Scientist Office of the Scottish Government Health and Social Care Directorates fund the Health Economics Research Unit (HERU). This study would not be possible without the families, patients, clinicians, nurses, research scientists, laboratory staff, and the wider Scottish Genomes Partnership team to whom we give grateful thanks.en
dc.format.extent15
dc.language.isoeng
dc.relation.ispartofJournal of Community Geneticsen
dc.rightsThis is a post-peer-review, pre-copyedit version of an article published in Journal of Community Genetics]. The final authenticated version is available online at: http://dx.doi.org/[insert DOI]en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.en
dc.subjectWhole Genome Sequencingen
dc.subjectDiagnostic Odysseyen
dc.subjectCosts and Benefitsen
dc.subjectEconomic Evaluationen
dc.subjectValuationen
dc.subjectR Medicineen
dc.subjectChief Scientist Office (CSO)en
dc.subjectSGP/1en
dc.subjectMedical Research Council (MRC)en
dc.subjectMC/PC/15080en
dc.subjectOtheren
dc.subjectSupplementary Informationen
dc.subject.lccRen
dc.titleContinuing the sequence? : Towards an Economic Evaluation of Whole Genome Sequencing for the Diagnosis of Rare Diseases in Scotlanden
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Economics Research Uniten
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1007/s12687-021-00541-4


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record